Columnist Michael Rosen predicted an interesting year in the life science realm, thanks in part to expiring patents, and so far he's been spot on. In this edition of Yer Biotech Blues, he cites Pfizer's acquisition of Wyeth as an example of what's ahead, and...
After eight years at the helm, Jim Leonhart has resigned as executive director of the Wisconsin Biotechnology and Medical Device Association. In announcing the resignation, the association said Leonhart would pursue opportunities that blend his interest in biotechnology and education. Meanwhile, the WBMDA's board of...
Menlo Park, Calif. - Geron Corp. (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. The clearance enables Geron...
A Boston-based orthopedic technology company whose chief executive has ties to the Madison biotechnology industry says the company would move to Madison if it secures angel funding in Wisconsin. Former ConjuGon executive and UW-Madison graduate Sal Braico, now CEO of Boston's Flex Biomedical, says the...
With many Big Pharma companies approaching the cliff of patent expiration, and recent changes in the executive suite at major companies, 2009 should be a year of transformation in the life science industry, writes columnist Michael Rosen. In this edition of Yer Biotech Blues, Rosen...
Centrose, a Madison-based biopharmaceutical company, has secured another patent from the U.S. Patent and Trademark Office for CarboConnect, a platform sugar chemistry that can improve the efficacy of pharma drugs. The patent is licensed through the Wisconsin Alumni Research Foundation, the licensing arm of the...
PhysioGenix Inc., which sells pre-clinical services to drug companies, said it plans to spin off a subsidiary that will attempt to create drugs out of compounds developed at the University of Wisconsin-Milwaukee. The spinoff will make a separate company of Neuro Amp LLC, which has an...
Marquette University and UW-Milwaukee have teamed up to license a compound for the treatment for schizophrenia to Promentis Pharmaceuticals, a start-up pharmaceutical company. Promentis was founded by Marquette professors David Baker and John Mantsch, and is managed with the help of with UWM chemistry professor...
Using cancer cells from an ovarian cancer patient and human embryonic stem cells, Israeli researchers have created a cancerous tumor in a mouse that mimics the way the tumor would develop in the patient's body. The result is a pre-clinical experimental model for cancer research...
A European provider of human embryonic stem cell products has signed a licensing agreement with the Wisconsin Alumni Research Foundation. Cellartis AB, which develops stem cell products for drug discovery, drug toxicity testing, and regenerative medicine, now has access to the American stem cell market. ...